Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 July 2005, Vol. 106, No. 1, pp. 40-42.
Prepublished online as a Blood First Edition Paper on March 24, 2005; DOI 10.1182/blood-2005-01-0319.


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-01-0319v1
106/1/40    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tardieu, M.
Right arrow Articles by Fischer, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tardieu, M.
Right arrow Articles by Fischer, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted January 25, 2005
Accepted March 2, 2005

Progressive neurological dysfunctions twenty years after allogeneic bone-marrow transplantation for Chediak-Higashi syndrome

Marc Tardieu*, Catherine Lacroix, Benedicte Neven, Pierre Bordigoni, Genevieve de Saint Basile, Stephane Blanche, and Alain Fischer

Service de Neurologie, Departement de Pediatrie et Laboratoire de Neuropathologie, Hopital Bicetre, Assistance Publique-Hopitaux de Paris, Le Kremlin Bicere, France
Unite d'Immunohematologie Pediatrique, Paris, France
Service de Pediatrie, Centre Hospitalier Universitaire, Nancy, France
INSERM U429, Hopital Necker, Assistance Publique-Hopitaux de Paris, Paris, France
Unite d'Immunohematologie Pediatrique, Paris, France; INSERM U429, Hopital Necker, Assistance Publique-Hopitaux de Paris, Paris, France

* Corresponding author; email: marc.tardieu{at}bct.ap-hop-paris.fr.

Three patients with Chediak-Higashi syndrome underwent allogeneic bone marrow transplantation between the ages of 2 9/12 and 7 years. The outcome was uneventful, with sustained mixed chimerism. No subsequent recurrent infections or hemophagocytic syndrome were observed. At the age of 22 to 24 years, these three patients developed a neurological deficit combining difficulty walking, loss of balance and tremor. Neurological evaluation demonstrated cerebellar ataxia and signs of peripheral neuropathy. Moderate axon loss and rarefaction of large myelinated fibers were observed on semi-thin sections of peripheral nerve. Cerebellar atrophy was detected by cerebral magnetic resonance imaging in two patients. We also reviewed the very long-term outcome of the other 11 patients with Chediak-Higashi syndrome who had received bone-marrow transplants at our center since 1981. All displayed neurological deficits or low cognitive abilities.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
J. Pachlopnik Schmid, D. Moshous, N. Boddaert, B. Neven, L. Dal Cortivo, M. Tardieu, M. Cavazzana-Calvo, S. Blanche, G. de Saint Basile, and A. Fischer
Hematopoietic stem cell transplantation in Griscelli syndrome type 2: a single-center report on 10 patients
Blood, July 2, 2009; 114(1): 211 - 218.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
W. Fiskus, M. Pranpat, M. Balasis, P. Bali, V. Estrella, S. Kumaraswamy, R. Rao, K. Rocha, B. Herger, F. Lee, et al.
Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate-Sensitive or Imatinib Mesylate-Resistant Chronic Myelogenous Leukemia Cells.
Clin. Cancer Res., October 1, 2006; 12(19): 5869 - 5878.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
T. R. Mahoney, Q. Liu, T. Itoh, S. Luo, G. Hadwiger, R. Vincent, Z.-W. Wang, M. Fukuda, and M. L. Nonet
Regulation of Synaptic Transmission by RAB-3 and RAB-27 in Caenorhabditis elegans
Mol. Biol. Cell, June 1, 2006; 17(6): 2617 - 2625.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
J. Baselga
Targeting Tyrosine Kinases in Cancer: The Second Wave.
Science, May 26, 2006; 312(5777): 1175 - 1178.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020